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Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in 
Alzheimer Disease, affecting ~ 40% to 60% of individuals with AD (AD with psychosis, AD+P). 
In comparison to AD subjects without psychosis, AD+P subjects have more rapid cognitive 
decline and poor outcomes. Prior studies have estimated the heritability of psychosis in AD at 
61%, but the underlying genetic sources of this risk are not known. We evaluated a Discovery 
Cohort of 2876 AD subjects with (N=1761) or without psychosis (N=1115). All subjects were 
genotyped using a custom genotyping array designed to evaluate SNPs with evidence of genetic 
association with AD+P and include SNPs affecting or putatively affecting risk for schizophrenia 
and Alzheimer disease. Results were replicated in an independent cohort of 2194 AD subjects with 
(N=734) or without psychosis (N=1460). We found that AD+P is associated with polygenic risk 
for a set of novel loci and inversely associated with polygenic risk for schizophrenia. Among the 
biologic pathways identified by the associations of schizophrenia SNPs with AD+P are endosomal 
trafficking, autophagy, and calcium channel signaling. These findings provide the first clear 
demonstration that AD+P is associated with common genetic variation. In addition, they provide 
an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. 
This provides an opportunity to leverage progress made in identifying the biologic effects of 
schizophrenia alleles to identify novel mechanisms protecting against more rapid cognitive decline 
and psychosis risk in AD.
Introduction
Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent 
in Alzheimer Disease (AD+Psychosis, AD+P), affecting ~ 40% to 60% of individuals with 
AD. In comparison to AD subjects without psychosis, AD+P subjects have more rapid 
cognitive decline and poor outcomes. Ropacki and Jeste1 comprehensively reviewed the 
literature on psychosis in AD from 1990 to 2003, identifying 55 studies comprised of 9,749 
subjects. More rapid cognitive decline was the most consistent correlate of AD+P compared 
to AD without psychosis (AD-P). More recent studies have continued to support the 
relationship between greater cognitive impairment, more rapid cognitive decline, and AD+P.
2–8
 AD+P is further associated with additional psychiatric and behavioral disturbances, the 
most frequent and troublesome of which are agitation9 and aggression10;11. AD+P leads to 
greater distress for family and caregivers12, greater functional impairment,13 higher 
institutionalization rates,14–17 worse health18 and increased mortality19 compared to AD-P 
patients.
Treatment of psychosis in AD patients has been suboptimal due to the limited efficacy of 
available drugs and their high toxicity in this age group. First line treatments are atypical 
antipsychotics, which have efficacy similar to conventional antipsychotics for AD+P, with 
lower rates of motor side effects.20 However, atypical and conventional antipsychotics have 
been associated with an increased risk of all-cause mortality after even short-term treatment.
20;21
 Other treatments, such as selective serotonin reuptake inhibitors, may have some 
efficacy22;23 and improved tolerability.24 Nevertheless, none of these treatments was derived 
to prevent or reverse an identified biology of AD+P, and there is no current data to suggest 
that any of these treatments effectively mitigate against the greater cognitive and functional 
decline associated with AD+P. It is thus imperative to develop an approach to promote 
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discovery regarding the biology of AD+P and identify opportunities to intervene to prevent 
its adverse trajectory.
We initially observed familial aggregation of AD+P,25 since replicated in two independent 
cohorts.4;26 These studies show a remarkable consistency in the estimated 3–4 fold increased 
odds of psychosis in a family member with AD, given the presence of psychosis in a 
proband with AD. Similarly, we used two of these cohorts to estimate the heritability of 
psychosis in AD as 61%.27;28 Thus, AD+P is likely to be strongly influenced by genetic 
variation. In keeping with these observations, we recently reported the first Genome-Wide 
Association Study (GWAS) of AD+P, evaluating 1,299 cases with AD+P and 735 
individuals characterized as AD-P. Although no single SNP demonstrated genome-wide 
significance, likely due to modest sample size, there was suggestive evidence for association 
with novel loci.
We further found a trend towards association with a group of 11 SNPs that had been 
identified in initial GWAS studies of schizophrenia and bipolar disorder.29 That latter 
finding also provided the biologically intriguing observation that the direction of 7/11 allelic 
effects on risk for AD+P were opposite that reported in the studies of psychiatric disorder 
subjects. Since the time of our prior report, genomic studies of schizophrenia risk have 
identified 128 SNPs in 108 loci that exceed genome-wide significance.30
Recently, the use of polygenic risk scores has emerged as an important approach for 
summarizing genetic effects of a set of SNPs. A polygenic score is a simple, subject-specific 
summary of the additive effects of alleles on a trait. When computed to predict subjects’ risk 
for a disorder, it is called a polygenic risk score. The score can be obtained from a limited 
set of SNPs, such as those reaching genome wide significance in association studies, or a 
larger set based on some other threshold 313233, or the entire genome 34;35. For example, 
when alleles at the 108 schizophrenia-associated loci were combined in a polygenic risk 
score they explained 3.4% of the liability to schizophrenia.30 For traits in which few or no 
individual SNPs reach genome wide significance, polygenic risk scores can provide initial 
evidence for true genetic association of the trait with the SNPs either included within the 
score or in close linkage disequilibrium 33, providing critical evidence in support of larger 
scale studies needed to identify the individual affected loci.
Here we follow up on our prior research in an expanded Discovery Cohort of 2876 AD 
subjects with and without psychosis. All subjects were genotyped using a custom chip 
designed to evaluate SNPs with evidence of genetic association, most prominently with AD
+P, although SNPs affecting or putatively affecting risk for schizophrenia and Alzheimer 
disease were also assessed. Results were replicated in an independent cohort of 2194 AD 
subjects with and without psychosis. We found that AD+P is associated with polygenic risk 
for a set of novel loci and inversely associated with polygenic risk for schizophrenia. These 
findings provide the first clear demonstration that AD+P is associated with common genetic 
variation. In addition, they provide an unbiased link between polygenic risk for 
schizophrenia and a lower risk of psychosis in AD. As efforts to identify the biologic effects 
of schizophrenia alleles progress, it may be possible to leverage these results to identify 
novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.
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Materials and Methods
An overview of the study design and workflow is shown in Figure 1.
Subjects
This study analyzed samples obtained from subjects in two cohorts, an initial Discovery 
Cohort and an independent Replication Cohort (Table 1). All subjects were diagnosed with 
possible, probable,36 or definite37 AD. Importantly, subjects with a primary diagnosis of 
Dementia with Lewy bodies38 were excluded. The above diagnoses resulted from diagnostic 
evaluations, cognitive testing, and in some cases neuropathologic assessment, conducted 
during subjects’ participation in the following programs as previously described: the 
University of Pittsburgh Alzheimer Disease Research Center (ADRC),39;40 the Genetic and 
Environmental Risk in AD Consortium 1 (UK),29;41;42 the National Institute on Aging’s 
Late Onset Alzheimer’s Disease Family Study (NIA-LOAD),4;28 the National Institute of 
Mental Health Genetics Initiative AD Cohort (NIMH),25 the Fundació ACE Barcelona 
Alzheimer Treatment and Research Center (ACE),41;43, the Cardiovascular Health Study 
(CHS),3;41 and a consortium of National Institute on Aging Alzheimer Disease Centers 
(ADC).44 Collection of clinical data and genetic samples were approved by each sites local 
Institutional Review Board or Medical Ethics Committee, as appropriate. Additional detail 
of the individual cohorts and assessment methodology is available in Supplementary 
Methods and Tables S1–S13.
Characterization of Psychosis
Subjects were characterized for the presence or absence of delusions and hallucinations 
within the individual studies using the CERAD behavioral rating scale45 (ADRC and NIA-
LOAD), Neuropsychiatric Inventory Questionnaire (NPI-Q,46 NIA-LOAD, ADC), NPI-Q 
Spanish Version47 (ACE), NPI48 (UK, CHS), and Brief Psychiatric Rating Scale49 (NIMH). 
Each of these instruments has established reliability in AD,4;50 and we have previously used 
all successfully in analyses of psychosis in AD subjects.3;4;6;27;39 Details of the application 
of these assessments for each cohort are provided in the Supplementary Methods. AD+P was 
defined by the presence of persistent hallucinations or delusions occurring during the course 
of the dementia, AD-P was defined by the absence of all symptoms at all assessments. 
Because psychotic symptoms typically emerge in the mild to moderate stages of AD4 
individuals without psychosis but who were still in the early stages of disease at their last 
assessment (Clinical Dementia Rating51 score <1, mini-mental state examination score52 
>20) were considered to be at substantial risk of developing AD+P later in their course. 
Thus, these individuals were excluded from the analysis. We have previously used these 
approaches to characterizing and defining AD+P and AD-P to demonstrate familial 
aggregation,4;25 heritability,27;28 genetic linkage,28;53 and suggestive genome-wide 
association29 with the AD+P phenotype.
Genotyping
DNA Preparation—Samples from outside sources were shipped on dry ice, stored, and 
processed by the Genomic Core Lab at the University of Pittsburgh. ACE samples were 
supplied as whole blood and genomic DNA was extracted using the Qiamp Blood Mini kit 
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(Qiagen, Valencia, CA). All other centers provided genomic DNA (ADRC, NIA-LOAD, 
NIMH, UK, ADC) or whole genome amplified DNA (CHS).
Custom Chip for Discovery Cohort—The Genomic Core Lab quantitated all samples 
by Pico Green (Thermo Fisher, Pittsburgh, PA) and diluted the DNA to 23ng/ul and shipped 
the plates on dry ice to Affymetrix (Los Angeles, CA) for genotyping. Plates also contained 
randomized duplicates. Affymetrix confirmed all DNA concentrations by Pico Green assay 
prior to genotyping. Genotyping used a custom designed Axiom® chip (see SNP selection 
below), and was performed using the Affymetrix GeneTitan® system as described in the 
axiom user manual54 with resultant genotype calls provided for QC and analysis.
iPlex Assay for Genotyping SCZ risk score SNPs and Replication Cohort 
Testing
iPlex Chemistry: Assays were designed with Assay Designer 4.0 (Agena) and analysis 
performed using iPlex Gold Genotyping Reagent Set (Agena, San Diego, CA) according to 
manufacturer’s instructions. Target loci were amplified within the samples by multiplex PCR 
in 1X PCR buffer containing 3.5 mM MgCl2, 25 mM dNTPs, 500 nM each of forward and 
reverse amplification primer within the multiplex pool and 2.5 U HotStar Taq. dNTPs and 
primers were removed by incubation with 0.5 U shrimp alkaline phosphotase (SAP) at 37 °C 
for 40 minutes. SAP was inactivated by incubation at 87 °C for 5 minutes. Single base 
extension was carried out in 0.2X iPLEX buffer plus, 1X termination mix (containing mass 
modified termination nucleotides), 1X iPLEX enzyme and primers at 0.84 μM, 1.04 μM and 
1.25 μM as appropriate to the relative mass of each primer. Following thermocycling, clean 
resin and water was added to the MassExtend reaction products. Samples were incubated in 
clean resin at room temperature with mixing for 5 minutes and centrifuged at 3200 × g for 5 
minutes.
Samples were then dispensed to a SpectraChip using the MassArray Nanodispenser 
according to manufacturer’s instructions. Spectra chips were loaded into the MassArray 
analyzer and spectra acquired for each sample. Genotype calls were made using Typer 4.0 
(Agena) by mass identification of extended primer peaks.
SNP Selection
Development of Custom Array for Discovery Cohort—The process of selecting 
SNPs for the genotyping array involved two principal stages. First SNPs were amalgamated 
based on genetic signal for association to a small set of phenotypes (Table S14). The bulk of 
the SNPs were included on the basis of association results from four contrasts reported in 
three genome-wide studies: a contrast of AD+P versus AD-P,29 AD+P versus controls,29 AD 
versus controls 55;56, and SCZ versus controls 32;57. An additional unpublished data set 
(described in58;59) of cis-eQTLs affecting gene expression and cis-eQTLs associated with 
age-related changes in gene expression was also used. For the first four genome-wide 
association studies (GWAS), SNPs with p-value less than a threshold of 0.01 were selected; 
for the eQTLs, the threshold was 0.001 and for the ‘aging’ eQTLs it was 0.05. Note that 
when a SNP was represented in more than one study, the minimum p-value in any of the 6 
datasets was taken as representative for the SNP. To interrogate copy number regions shown 
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to be associated with schizophrenia, 1574 SNPs were included (1q21.1, 3q29, 15q11.2–
15q13.3, 16p13.1, 16p11.2 and 22q11.2, recently reviewed in 60; and 7q11.2361). Finally a 
small fraction of SNPs were chosen to cover four genes of interest regarding psychotic 
disorders (SCZ target genes: NRXN1,60 ERBB4,62 PAK2,63 CHRNA764) or were 
nominated from unpublished AD studies (UK SNPs).
Second, SNPs were retained for genotyping by a winnowing process. This process involved 
removing redundant SNPs, those that could not be genotyped on the Axiom platform, or 
SNPs not present in 1000 genomes. Of the SNPs passing this step, all SNPs with a minimum 
p-value < 0.0001 for any study were retained. For the remainder, by using a LD clumping 
process, we removed SNPs in LD with the retained SNPs (r2 > 0.9) and retained additional 
SNPs with the smallest p-value in “independent” clumps (r2 < 0.9) by pruning SNPs with 
Plink (maximum distance for pruning was 5 kb, window width was 25 SNPs, sliding step 
was 5 SNPs).
SNP Selection for SCZ Risk Score Testing and Follow-up Genotyping in 
Replication Cohort—For SCZ risk score testing in each cohort we targeted the 128 GWA 
significant SNPs reported in 30, although not all could be genotyped. Follow-up genotyping 
in the Replication Cohort also selected SNPs from our custom array that passed Quality 
Control and with P < 0.0001 for the contrast of AD+P versus AD-P. For the replication 
cohort we selected Ancestry Informative Markers (AIMs) for European Ancestry based on 
the results in 65 Specifically, based on results found in with Supplementary Table 1 of Kosoy 
et al. 65, we selected their “Top 96” European AIMs, of which 82 could be genotyped on the 
Sequenom platform and 79 passed Quality Control.
Quality Control
QC was performed at the individual level first, then at the SNP level conditional on 
individual-level data passing QC and individuals of European ancestry. Details of QC are 
given in Supplementary Material. In brief, genetic data for samples were retained if their 
nominal sex agreed with genetically determined sex; heterozygosity rate, per subject, 
revealed no evidence of contamination by other samples; genetic data for subjects expected 
to be unrelated suggested this were true; and call rate of SNPs > 96.5% per sample. Next 
ancestry of subjects in the Discovery Cohort was determined using dacGem in GemTools 
based on 5712 autosomal markers with non-call rate ≤ 0.001, minor allele frequency (MAF) 
≥ 0.05, and r2 ≤ 0.20. The samples were separated into 5 clusters based on 3 significant 
ancestry dimensions, four of which likely represent European ancestry and two of these 
contain the bulk of the subjects (≈ 66%). SNP QC was performed on data from these two 
clusters. SNPs passed QC if their call rate was > 95%, MAF was ≥ 0.01 and the exact Hardy 
Weinberg Equilibrium p-value was > 0.005. Ancestry of samples in the Replication Cohort 
was determined using GemTools based on 79 autosomal Ancestry Informative Markers. The 
samples separated into 3 clusters based on 2 significant ancestry dimensions (Figure S3).
Statistical Analysis
Association between diagnosis and minor allele count for each SNP was assessed using 
logistic regression. For the Discovery Cohort, the model also accounted for first 5 ancestry 
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dimensions whereas for the Replication Cohort it accounted for two. Because some subjects 
in the Discovery Cohort were related as siblings, inference relied on the generalized 
estimating equation (gee) approach implemented in the statistical software R, assuming full 
siblings were correlated at 0.5 (i.e., twice the kinship coefficient for full siblings).
To predict affection status using polygenic risk scores, either unweighted or weighted risk 
scores could be computed: the unweighted score for a subject is the sum of the count of risk 
alleles over all genotypes for that subject; a weighted score uses the same principle, but the 
count of risk alleles per SNP is adjusted by a function of the estimated effect of the SNP on 
risk (log odds ratio). Both unweighted and weighted scores for AD+P risk were calculated. 
Scores were derived from results from the Discovery Cohort and then used to predict AD+P 
status based on genotypes for each subject in the Replication Cohort. For the SCZ-risk 
score, only a subset of the 128 GWA significant SNPs could be genotyped. For genotyped 
SNPs, an unweighted score for each AD subject was estimated.
Results
Association of AD+P with novel common variants
Not all of the subjects genotyped on the Axiom array were independent of our previously 
reported GWAS meta-analysis.29 Of the 2876 Discovery Cohort subjects described in Table 
1a, 1157 of these subjects were in our prior GWAS and the remainder, 1799 subjects (969 
AD+P and 750 AD-P), were independent. We, therefore, evaluated association both as a 
joint analysis of the sample sets (mega-analysis) and by analysis of the independent subjects. 
For the former we use the traditional threshold for GWAS significance, 5×10−8; for the latter 
we used a somewhat more lenient threshold based sample sizes and the number of SNPs 
tested on both samples (5.6×10−8).
For neither the joint analysis (Fig 2a) nor the independent analysis threshold (results not 
shown) was any SNP significantly associated with risk for AD+P. For the joint analysis there 
were 67 SNPs with P < 5 × 10−4 (Fig 2a). To test these SNPs we empaneled a Replication 
Cohort (Table 1b). We successfully designed and assayed either the SNP or a proxy in 
perfect LD for 60/67 target SNPs.
We next used the results from the Discovery Cohort to assign the “risk allele” at each of the 
60 SNPs. Then, by counting the number of risk alleles carried by subjects in the Replication 
Cohort, we formed an unweighted risk score for each subject. This score significantly 
predicted AD+P status in the Replication Cohort, showing clear evidence for association 
(Table 2a). The same is true for a weighted score (Table 2a).
Moreover, although no single SNP was significantly associated with risk for AD+P within or 
across stages, and only three SNPs approached individual significance when combining 
stages (Fig 2b and Table 3), 41 out of the 60 SNPs had the same risk allele for both the 
Discovery and Replication Cohorts (Fig 2b; Fisher Exact Test, p = 0.0062). The 3 SNPs that 
approached significance are in RP11-541P9.3 (an antisense transcript) located 5′ to Cyclin 
G1 (CCNG1).
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Association of AD+P with polygenic variation associated with schizophrenia
We previously described a significant association between AD+P and a summary statistic 
from a small number of putative schizophrenia and bipolar disorder risk alleles. Curiously, 
however, the direction of risk for most alleles was opposite in AD+P.29 Recently, 128 
genome-wide significant SNPs at 108 independent loci have been identified in 
schizophrenia.30 When these loci were combined into a polygenic risk score they explained 
~3.4% of the variance in schizophrenia risk.30 We successfully genotyped 101 of these SNPs 
in the Discovery Cohort. We found that the corresponding unweighted risk score was 
significantly associated with AD+P (Nagelkerke’s pseudo R2 = 0.32%, P = 0.006). We then 
genotyped the schizophrenia SNPs in the Replication Cohort. For this analysis, 94 SNPs 
remained after QC. Results clearly replicated, with close agreement between the two cohorts 
(Table 2b).
Of note, as in our earlier report,29 increasing schizophrenia polygenic risk score was 
associated with reduced risk of psychosis in AD. Consider, for example, its relationship 
within the Discovery Cohort. To better illustrate this relationship, we calculated an AD+P 
aligned risk score. For each of the SNPs comprising the schizophrenia polygenic risk score, 
the allele that increased the risk of developing AD+P was determined and a weighted sum of 
risks was then computed for each of the samples. The correlation between the AD+P aligned 
risk scores and the schizophrenia risk scores was −0.159 (p = 5.5e-18, Fig 3).
It should be noted that despite the overall protective effects of schizophrenia polygenic risk 
score on AD+P risk, a smaller number of individual schizophrenia risk SNPs were 
associated with increased risk of AD+P. Table 4a details the 20 SNPs that most consistently 
(as defined by the minimum of the sum of their individual SNP regression coefficients from 
the analysis of the Discovery and Replication cohorts) were associated with reduced AD+P 
risk. Table 4b provides similar information for the 10 SNPs that most consistently were 
associated with increased AD+P risk in the two cohorts.
Discussion
Psychosis occurs in approximately half of individuals affected by AD, serving to identify a 
subgroup with more rapid decline and poor outcomes. We, and others, have hypothesized 
that common genetic variation may contribute to the risk of psychosis in AD, based in part 
on evidence that AD+P aggregates in families, with an estimated heritability of 61%. 
However, prior studies of the association of common genetic variation with AD+P have been 
inconclusive.66;67 We now provide the first clear evidence in support of an association of AD
+P with both a unique set of common variants, and with a set of common variants associated 
with risk for schizophrenia.
Several potential methodologic issues in determining the psychosis phenotype are important 
to consider in evaluating our findings. First, the need to aggregate multiple cohorts so as to 
have sufficient power for detection of association with common genetic variation meant that 
we included sites in which different rating scales were used for ascertainment of psychosis, 
which could have contributed noise to our phenotypic classifications. Such a limitation, if 
present, would have reduced our power to detect differences between groups. Thus, it speaks 
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to the robustness of our findings that despite this potential limitation, we were able to 
replicate associations across two independent, somewhat heterogeneous cohorts. Perhaps 
this result is not surprising, in that significant familial aggregation of AD+P was previously 
identified in three separate family cohorts, each of which relied primarily on a different 
behavioral rating scale.4;25;26 Second, we chose to consider delusions and hallucinations 
together as a psychosis syndrome rather than evaluate them individually. The best approach 
to this issue likely depends on the question being asked. For example, when evaluating 
functional neuroanatomy separation of these symptoms could make most sense. However, 
for genetic studies, there is substantial support for grouping these symptoms. Specifically, 
studies demonstrating familial aggregation of AD+P4;25;26 have all used this joint definition, 
establishing it as suitable for genetic investigation. Similar data in support of individual 
psychotic symptoms does not exist. Finally, the relationships between clinical Dementia 
with Lewy Body diagnoses (DLB), Lewy Body neuropathology, and AD+P is complex.67;68 
In brief, DLB pathology may contribute to some proportion, but clearly not account for 
most, of the occurrence of AD+P. Nevertheless, all sites in the current study used standard 
diagnostic criteria to identify individuals with probable Lewy Body Dementia and exclude 
them from analysis (the one exception being the NIMH family study which predated the 
generation of DLB criteria, but did exclude individuals with parkinsonism or prominent 
early behavioral disturbance.69 As practical evidence that these diagnostic approaches are 
sufficiently rigorous to identify AD separately from DLB, the sites included in the current 
study have successfully contributed to discovery of common variants for AD risk.42
We identified a set of SNPs with suggestive association with AD+P in our Discovery Cohort, 
confirming this polygenic association with AD+P in an independent Replication Cohort. 
Although no individual SNP reached genome-wide significance in the meta-analysis, the 
strongest associations were seen with three SNPs, rs300215, rs6859958 and rs999581, 
within a single locus. The function of the antisense transcript, RP11-541P9.3, is not known. 
However, it is located 5′ to CCNG1 and is therefore likely to regulate CCNG1 expression. 
In support of this interpretation, rs6859958 and rs999581 have been shown to be eQTLs for 
CCNG1 in some tissues.70 Most cyclins activate cyclin dependent kinases, including CDK5, 
a Tau kinase that promotes phospho-Tau aggregation.71 In contrast, CCNG1 has been 
proposed to competitively inhibit the activation of cyclin dependent kinases by other cyclins.
72
 Whether increased levels of Cyclin G1, the protein product of CCNG1, is therefore 
protective against pathological phosphorylation of Tau by CDK5 is not established. 
Nonetheless, in neocortex of AD subjects Cyclin G1 levels are increased in pyramidal 
neurons lacking Tau aggregates and are undetectable in those pyramidal neurons containing 
aggregated phospho-Tau.73 Because the strongest brain correlate of psychosis in AD is 
excess phosphorylation of tau (in comparison to the degree of Tau phosphorylation in AD 
subjects without psychosis),67 CCNG1 is thus also a strong functional candidate for AD+P 
risk.
We also identified and confirmed an association of polygenic risk for schizophrenia with a 
reduced risk of AD+P. At present, there is little convergent data from family studies to 
inform on the relationship of schizophrenia risk to AD+P.9;74 The inverse nature of the 
association between schizophrenia risk score and AD+P may seem counterintuitive at first. 
In fact, it was the counterintuitive nature of our findings that motivated us to attempt to 
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independently replicate them, finding a nearly identical association in a second large cohort. 
In contrast to our findings, schizophrenia has been shown to share polygenic risk with a 
number of complex disorders, such as autism and bipolar illness, which may include 
psychotic symptoms as part of the expressed phenotype.75 Unlike AD+P, these are disorders 
of early, or late, neurodevelopment and thus do not occur in the context of 
neurodegeneration.
Possible genetic mechanisms underlying how the 108 schizophrenia-associated loci confer 
an increased risk of schizophrenia are just now emerging.76–78 How these loci may lead to 
reduced AD+P risk cannot be asserted, but a few exemplars are worth discussion. First, a 
locus may alter expression of a single gene that has effects during neurodevelopment which 
increase schizophrenia risk, but when the same altered expression occurs in a brain with an 
active AD neurodegenerative process, it is protective. For example, rs75968099 is an eQTL 
for LRRFIP2 (Table 4), the gene encoding Leucine-rich Repeat Flightless-interacting 
Protein 2, a regulator of Toll-like receptor 4-mediated signaling in response to inflammatory 
stimuli. Toll-like receptor 4 signaling helps activate microglia to clear toxic amyloid β from 
the brain of an AD patient in early disease stages,79 whereas microglial activation may 
contribute to excess synaptic elimination in development, increasing risk for schizophrenia.
76
 Second, a locus may regulate the expression of gene transcription differently during early 
neurodevelopment than in the adult brain. Such an effect has recently been described for the 
schizophrenia risk locus defined by rs55833108, and may similarly be present at loci that 
confer opposing risks for schizophrenia and AD+P.78 A third scenario might result from the 
observation that a SNP and/or locus may be an eQTL for more than one gene. For example, 
the locus on chromosome 17 defined by rs8082590 was recently reported to show consistent 
disease and eQTL associations for two genes, TOM1L2 and DRG2,77 encoding Target Of 
Myb1 Like 2 Membrane Trafficking Protein and Developmentally Regulated GTP Binding 
Protein 2, respectively. Developmentally Regulated GTP Binding Protein 2 deactivates the 
early endosome regulator, Ras-related protein Rab-5A.80 Thus it is strongly positioned to 
impact glutamate neurotransmission, a process implicated in the pathogenesis of 
schizophrenia, via effects on neurotransmitter release81 and on AMPA receptor 
internalization.82 In contrast, Target Of Myb1 Like 2 Membrane Trafficking Protein is 
necessary for delivery of endosome cargo to autophagosomes, which target protein 
aggregates and damaged organelles to lysosomes for degradation.83 The autophagy pathway 
is strongly implicated in the pathogenesis of AD84 and, more recently, of schizophrenia,85 
and is also downstream of Toll-like receptor 4 signaling.86 Finally, we note that the above 
examples are not comprehensive. Other mechanisms may also contribute to different impacts 
of loci on risk for schizophrenia and AD+P.
As indicated in Table 4b, we also identified SNPs that showed the same direction of effect 
for schizophrenia and AD+P risk, Notable among these were two intronic SNPs located in 
CACNA1C, the gene encoding the voltage-dependent L-type calcium channel subunit 
alpha-1C. Although the genetic mechanism underlying these associations remains an area of 
active inquiry,87 convergent data suggests that schizophrenia is associated with reduced 
voltage-dependent calcium channel function.88–90 How reductions in voltage-dependent 
calcium channel function may further increase AD+P risk is not known, however, 
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impairments of intracellular Ca2+ homeostasis are present in AD, and can contribute to 
synaptic dysfunction and cognitive impairments.91
We recently estimated the annual incidence of psychosis in AD at 10%.40 Thus there is an 
opportunity to intervene prior to psychosis onset if individual predictors can be identified. 
Although currently no treatments are established for prevention of AD+P, selective serotonin 
reuptake inhibitors have some efficacy for treating it,22;23 and they have acceptable 
tolerability. Non-pharmacologic treatments may also offer benefit for treating AD+P 
(reviewed in92 and40) and could be adapted for prevention. It is thus worth considering 
whether genetic variants that associate with psychosis may serve as biomarkers to predict 
AD+P risk and the associated more rapidly declining cognitive trajectory. Because 
individual SNP relative risks are typically small, polygenic risk scores have greater 
predictive power.31;93 We observed a very modest explanatory power of both the 60 SNP 
and the schizophrenia polygenic risk scores, each accounting for less than 1% of the AD+P 
risk. None of these effects is large enough to yield meaningful clinical prediction at present. 
Still we note that these polygenic scores could have a different magnitude of effect on 
prediction of a related, clinically relevant construct, such as time to onset of psychosis. 
However, the development of predictive approaches would clearly benefit from the 
identification of additional risk loci. Nevertheless, the current findings are a step forward in 
the development of prevention for psychosis in AD.
In that regard it is noteworthy that our custom array, used to evaluate the Discovery Cohort, 
was derived, in part, from the one existing GWAS of AD+P. That earlier GWAS was 
underpowered and limited in the number of loci interrogated.29 As a consequence it is likely 
that many SNPs and loci that contribute meaningfully to AD+P risk were not tested in the 
current study. Despite this limitation, the current study provides confirmation of the 
hypothesis that AD+P is associated with common genetic variation. As such, it provides 
strong support for unbiased genome-wide scans of larger cohorts of AD+P and AD-P 
subjects, which will surely identify individual AD+P risk loci and develop more strongly 
predictive polygenic risk scores.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This study was supported by the following federal grants: AG027224 (RAS), AG005133 (RAS), BX000452 (RAS), 
MH057881 (BD), AG030653 (MIK), AG041718(MIK), and MH093723 (ELS). This project used the University of 
Pittsburgh HSCRF Genomics Research Core iPlex and Specimen Processing services. Cardiff University was 
supported by the Wellcome Trust, Medical Research Council (MRC) and/or Alzheimer’s Research UK (ARUK) 
and the Welsh Assembly Government (RS & JW).
The content is solely the responsibility of the authors and does not necessarily represent the official views of the 
National Institutes of Health, the Department of Veterans Affairs, or the United States Government.
DeMichele-Sweet et al. Page 11
Mol Psychiatry. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Reference List
1. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer’s disease: a 
review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005; 162:2022–30. [PubMed: 
16263838] 
2. Weamer EA, Emanuel JE, Varon D, Miyahara S, Wilkosz PA, Lopez OL, et al. The relationship of 
excess cognitive impairment in MCI and early Alzheimer’s disease to the subsequent emergence of 
psychosis. Int Psychogeriatr. 2009; 21:78–85. [PubMed: 18814807] 
3. Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, DeMichele-Sweet MA, et al. Trajectory 
of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular 
health study. Am J Geriatr Psychiatry. 2011; 19:160–68. [PubMed: 20808116] 
4. Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R. Assessment and familial aggregation of 
psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer’s 
Disease Family Study. Brain. 2010; 133:1155–62. [PubMed: 20147454] 
5. Seltman HJ, Mitchell S, Sweet RA. A Bayesian model of psychosis symptom trajectory in 
Alzheimer’s disease. Int J Geriatr Psychiatry. 2016; 31:204–10. [PubMed: 26216660] 
6. Sweet RA, Seltman H, Emanuel JE, Lopez OL, Becker JT, Bis JC, et al. Effect of Alzheimer’s 
disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. Am J 
Psychiatry. 2012; 169:954–62. [PubMed: 22952074] 
7. Koppel J, Sunday S, Goldberg TE, Davies P, Christen E, Greenwald BS. Psychosis in Alzheimer’s 
disease is associated with frontal metabolic impairment and accelerated decline in working memory: 
findings from the Alzheimer’s Disease Neuroimaging Initiative. Am J Geriatr Psychiatry. 2014; 
22:698–707. [PubMed: 23672944] 
8. Koppel J, Goldberg TE, Gordon ML, Huey E, Davies P, Keehlisen L, et al. Relationships between 
behavioral syndromes and cognitive domains in Alzheimer disease: the impact of mood and 
psychosis. Am J Geriatr Psychiatry. 2012; 20:994–1000. [PubMed: 22048323] 
9. Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and associated factors in 
Alzheimer’s disease. J Neuropsychiatry. 1991; 3:371–76.
10. Gilley DW, Wilson RS, Beckett LA, Evans DA. Psychotic symptoms and physically aggressive 
behavior in Alzheimer’s disease. J Am Geriatr Soc. 1997; 45:1074–79. [PubMed: 9288014] 
11. Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR 
polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in 
Alzheimer’s disease. Int Psychogeriatr. 2001; 13:401–09. [PubMed: 12003247] 
12. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the 
impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory 
Caregiver Distress Scale. J Am Geriatr Soc. 1998; 46:210–15. [PubMed: 9475452] 
13. Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, et al. Delusions 
and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005; 
62:1601–08. [PubMed: 16216946] 
14. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982; 248:333–35. 
[PubMed: 7087127] 
15. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. Psychiatric medication and 
abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol. 1999; 
56:1266–72. [PubMed: 10520944] 
16. Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in 
demented patients with delusions. J Geriatr Psychiatry Neurol. 1996; 9:123–26. [PubMed: 
8873875] 
17. Cummings JL, Diaz C, Levy M, Binetti G, Litvan II. Neuropsychiatric Syndromes in 
Neurodegenerative Disease: Frequency and Signficance. Semin Clin Neuropsychiatry. 1996; 
1:241–47. [PubMed: 10320427] 
18. Bassiony MM, Steinberg M, Rosenblatt A, Baker A, Lyketsos CG. Delusions and hallucinations in 
Alzheimer’s disease: Prevalence and clinical correlates. Int J Geriatr Psychiatry. 2000; 15:99–107. 
[PubMed: 10679840] 
DeMichele-Sweet et al. Page 12
Mol Psychiatry. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
19. Wilson RS, Tang Y, Aggarwal NT, Gilley DW, Mccann JJ, Bienias JL, et al. Hallucinations, 
cognitive decline, and death in Alzheimer’s disease. Neuroepidemiology. 2006; 26:68–75. 
[PubMed: 16352909] 
20. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for 
dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006; 
14:191–210. [PubMed: 16505124] 
21. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, et al. Differential risk of death 
in older residents in nursing homes prescribed specific antipsychotic drugs: population based 
cohort study. BMJ. 2012; 344:e977. [PubMed: 22362541] 
22. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. A randomized, 
double-blind, placebo-controlled comparison of citalopram and perphenazine for the acute 
treatment of psychosis and behavioral disturbances associated with dementia. Am J Psychiatry. 
2002; 159:460–65. [PubMed: 11870012] 
23. Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, et al. Effects of 
Citalopram on Neuropsychiatric Symptoms in Alzheimer’s Dementia: Evidence From the CitAD 
Study. Am J Psychiatry. 2016; 173:473–80. [PubMed: 27032628] 
24. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, Cunningham F, et al. Mortality risk 
in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J 
Psychiatry. 2007; 164:1568–76. [PubMed: 17898349] 
25. Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST. Increased familial risk of the 
psychotic phenotype of Alzheimer disease. Neurology. 2002; 58:907–11. [PubMed: 11914406] 
26. Hollingworth P, Hamshere ML, Holmans PA, O’Donovan MC, Sims R, Powell J, et al. Increased 
familial risk and genomewide significant linkage for Alzheimer’s disease with psychosis. Am J 
Med Genet B Neuropsychiatr Genet. 2007; 144B:841–48. [PubMed: 17492769] 
27. Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Heritability of 
psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005; 13:624–27. [PubMed: 16009739] 
28. Barral S, Vardarajan BN, Reyes-Dumeyer D, Faber KM, Bird TD, Tsuang D, et al. Genetic variants 
associated with susceptibility to psychosis in late-onset Alzheimer’s disease families. Neurobiol 
Aging. 2015; 36:3116.
29. Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, et al. Genome-wide association 
study of Alzheimer’s disease with psychotic symptoms. Mol Psychiatry. 2012; 17:1316–27. 
[PubMed: 22005930] 
30. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511:421–27. 
[PubMed: 25056061] 
31. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, et al. Common 
polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 
460:748–52. [PubMed: 19571811] 
32. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011; 43:969–
76. [PubMed: 21926974] 
33. Anney R, Klei L, Pinto D, Almeida J, Bacchelli E, Baird G, et al. Individual common variants exert 
weak effects on the risk for autism spectrum disorders. Hum Mol Genet. 2012; 21:4781–92. 
[PubMed: 22843504] 
34. de Los CG, Vazquez AI, Fernando R, Klimentidis YC, Sorensen D. Prediction of complex human 
traits using the genomic best linear unbiased predictor. PLoS Genet. 2013; 9:e1003608. [PubMed: 
23874214] 
35. Vazquez AI, Klimentidis YC, Dhurandhar EJ, Veturi YC, Paerez-Rodriguez P. Assessment of 
whole-genome regression for type II diabetes. PLoS One. 2015; 10:e0123818. [PubMed: 
25885636] 
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of 
Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of 
Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984; 
34:939–44. [PubMed: 6610841] 
37. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to 
establish a registry for Alzheimer’s disease (CERAD). Part II Standardization of the 
DeMichele-Sweet et al. Page 13
Mol Psychiatry. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
neuropathologic assessment of Alzheimer’s disease. Neurology. 1991; 41:479–86. [PubMed: 
2011243] 
38. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and 
management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 
2005; 65:1863–72. [PubMed: 16237129] 
39. DeMichele-Sweet MA, Klei L, Devlin B, Ferrell RE, Weamer EA, Emanuel JE, et al. No 
association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol 
Aging. 2011; 32:555–11.
40. Weamer EA, DeMichele-Sweet MA, Cloonan YK, Lopez OL, Sweet RA. Incident Psychosis in 
Subjects With Mild Cognitive Impairment or Alzheimer’s Disease. J Clin Psychiatry. 2016; 
77:e1564–e1569. [PubMed: 28086011] 
41. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide 
analysis of genetic loci associated with Alzheimer disease. JAMA. 2010; 303:1832–40. [PubMed: 
20460622] 
42. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis 
of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 
2013; 45:1452–58. [PubMed: 24162737] 
43. Lambert MJ, Hatch DR, Kingston MD, Edwards BC. Zung, Beck, and Hamilton Rating Scales as 
measures of treatment outcome: A meta-analytic comparison. J Consult Clin Psychol. 1986; 
54:54–59. [PubMed: 3958302] 
44. DeMichele-Sweet MA, Lopez OL, Sweet RA. Psychosis in Alzheimer’s disease in the national 
Alzheimer’s disease coordinating center uniform data set: clinical correlates and association with 
apolipoprotein e. Int J Alzheimers Dis. 2011
45. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, et al. The behavior 
rating scale for dementia of the Consortium to Establish a Registry for Alzheimer’s Disease. Am J 
Psychiatry. 1995; 152:1349–57. [PubMed: 7653692] 
46. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the 
NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 
2000; 12:233–39. [PubMed: 11001602] 
47. Boada M, Cejudo JC, Tarraga L, Lopez OL, Kaufer D. Neuropsychiatric Inventory Questionnaire 
(NPI-Q): Spanish validation of a brief clinical form of the Neuropsychiatric inventory (NPI). 
Neurologia. 2002; 17:317–23. [PubMed: 12084358] 
48. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The 
neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. 
Neurology. 1994; 44:2308–14. [PubMed: 7991117] 
49. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962; 10:799–812.
50. Zubenko GS, Rosen J, Sweet RA, Mulsant BH, Rifai AH. Impact of psychiatric hospitalization on 
behavioral complications of Alzheimer’s disease. Am J Psychiatry. 1992; 149:1484–91. [PubMed: 
1357991] 
51. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of 
dementia. Br J Psychiatry. 1982; 140:566–72. [PubMed: 7104545] 
52. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state” A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr” Res. 1975; 12:189–98. [PubMed: 
1202204] 
53. Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nimgaonkar VL, Sweet RA. Linkage analysis 
of Alzheimer disease with psychosis. Neurology. 2002; 59:118–20. [PubMed: 12105318] 
54. Affymetrix axiom assay user manual. 2016
55. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at 
MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. 
Nat Genet. 2011; 43:436–41. [PubMed: 21460841] 
56. 2016. https://www.niagads.org/dataset/ng00027
57. SCZ1 Dataset. 2016
DeMichele-Sweet et al. Page 14
Mol Psychiatry. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
58. Lin CW, Chang LC, Tseng GC, Kirkwood CM, Sibille EL, Sweet RA. VSNL1 Co-Expression 
Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer’s Disease 
Pathways. Front Psychiatry. 2015; 6:30. [PubMed: 25806004] 
59. Seney ML, Chang LC, Oh H, Wang X, Tseng GC, Lewis DA, et al. The Role of Genetic Sex in 
Affect Regulation and Expression of GABA-Related Genes Across Species. Front Psychiatry. 
2013; 4:104. [PubMed: 24062698] 
60. Kirov G. CNVs in neuropsychiatric disorders. Hum Mol Genet. 2015; 24:R45–R49. [PubMed: 
26130694] 
61. Mulle JG, Pulver AE, McGrath JA, Wolyniec PS, Dodd AF, Cutler DJ, et al. Reciprocal duplication 
of the Williams-Beuren syndrome deletion on chromosome 7q11. 23 is associated with 
schizophrenia. Biol Psychiatry. 2014; 75:371–77. [PubMed: 23871472] 
62. Banerjee A, MacDonald ML, Borgmann-Winter KE, Hahn CG. Neuregulin 1-erbB4 pathway in 
schizophrenia: From genes to an interactome. Brain Res Bull. 2010; 83:132–39. [PubMed: 
20433909] 
63. Mulle JG, Dodd AF, McGrath JA, Wolyniec PS, Mitchell AA, Shetty AC, et al. Microdeletions of 
3q29 confer high risk for schizophrenia. Am J Hum Genet. 2010; 87:229–36. [PubMed: 
20691406] 
64. Freedman R, Leonard S, Gault JM, Hopkins J, Cloninger CR, Kaufmann CA, et al. Linkage 
disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic 
acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet. 2001; 105:20–22. [PubMed: 
11424985] 
65. Kosoy R, Nassir R, Tian C, White PA, Butler LM, Silva G, et al. Ancestry informative marker sets 
for determining continental origin and admixture proportions in common populations in America. 
Hum Mutat. 2009; 30:69–78. [PubMed: 18683858] 
66. DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer’s disease: a review. J 
Alzheimers Dis. 2010; 19:761–80. [PubMed: 20157235] 
67. Murray PS, Kumar S, DeMichele-Sweet MA, Sweet RA. Psychosis in Alzheimer’s Disease. Biol 
Psychiatry. 2014; 75:542–52. [PubMed: 24103379] 
68. Sweet RA, Nimgaonkar VL, Devlin B, Jeste DV. Psychotic symptoms in Alzheimer disease: 
evidence for a distinct phenotype. Mol Psychiatry. 2003; 8:383–92. [PubMed: 12740595] 
69. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of 
NINCDS-ADRDA criteria for Alzheimer’s disease. The National Institute of Mental Health 
Genetics Initiative. Arch Neurol. 1994; 51:1198–204. [PubMed: 7986174] 
70. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic 
identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013; 
45:1238–43. [PubMed: 24013639] 
71. Wilkaniec A, Czapski GA, Adamczyk A. Cdk5 at crossroads of protein oligomerization in 
neurodegenerative diseases: facts and hypotheses. J Neurochem. 2016; 136:222–33. [PubMed: 
26376455] 
72. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. 
EMBO J. 1994; 13:4816–22. [PubMed: 7957050] 
73. Jordan-Sciutto KL, Morgan K, Bowser R. Increased Cyclin G1 Immunoreactivity During 
Alzheimer’s Disease. J Alzheimers Dis. 1999; 1:409–17. [PubMed: 12214116] 
74. Kotrla KJ, Chacko RC, Harper RG, Doody R. Clinical variables associated with psychosis in 
Alzheimer’s disease. Am J Psychiatry. 1995; 152:1377–79. [PubMed: 7653698] 
75. Smoller JW, Ripke S, Lee SH. Identification of risk loci with shared effects on five major 
psychiatric disorders: a genome-wide analysis. Lancet. 2013; 381:1371–79. [PubMed: 23453885] 
76. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk 
from complex variation of complement component 4. Nature. 2016; 530:177–83. [PubMed: 
26814963] 
77. Fromer M, Roussos P, Sieberts SK, Johnson JS, Kavanagh DH, Perumal TM, et al. Gene 
expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci. 2016; 
19:1442–53. [PubMed: 27668389] 
DeMichele-Sweet et al. Page 15
Mol Psychiatry. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
78. Li M, Jaffe AE, Straub RE, Tao R, Shin JH, Wang Y, et al. A human-specific AS3MT isoform and 
BORCS7 are molecular risk factors in the 10q24. 2 schizophrenia-associated locus. Nat Med. 
2016; 22:649–56. [PubMed: 27158905] 
79. Gambuzza ME, Sofo V, Salmeri FM, Soraci L, Marino S, Bramanti P. Toll-like receptors in 
Alzheimer’s disease: a therapeutic perspective. CNS Neurol Disord Drug Targets. 2014; 13:1542–
58. [PubMed: 25106635] 
80. Mani M, Lee UH, Yoon NA, Kim HJ, Ko MS, Seol W, et al. Developmentally regulated GTP-
binding protein 2 coordinates Rab5 activity and transferrin recycling. Mol Biol Cell. 2016; 
27:334–48. [PubMed: 26582392] 
81. Wucherpfennig T, Wilsch-Brauninger M, Gonzalez-Gaitan M. Role of Drosophila Rab5 during 
endosomal trafficking at the synapse and evoked neurotransmitter release. J Cell Biol. 2003; 
161:609–24. [PubMed: 12743108] 
82. Brown TC, Tran IC, Backos DS, Esteban JA. NMDA receptor-dependent activation of the small 
GTPase Rab5 drives the removal of synaptic AMPA receptors during hippocampal LTD. Neuron. 
2005; 45:81–94. [PubMed: 15629704] 
83. Tumbarello DA, Waxse BJ, Arden SD, Bright NA, Kendrick-Jones J, Buss F. Autophagy receptors 
link myosin VI to autophagosomes to mediate Tom1-dependent autophagosome maturation and 
fusion with the lysosome. Nat Cell Biol. 2012; 14:1024–35. [PubMed: 23023224] 
84. Li L, Zhang X, Le W. Autophagy dysfunction in Alzheimer’s disease. Neurodegener Dis. 2010; 
7:265–71. [PubMed: 20551691] 
85. Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, et al. 
Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry. 2015; 20:126–
32. [PubMed: 24365867] 
86. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-like receptor 4 is a 
sensor for autophagy associated with innate immunity. Immunity. 2007; 27:135–44. [PubMed: 
17658277] 
87. Eckart N, Song Q, Yang R, Wang R, Zhu H, McCallion AS, et al. Functional Characterization of 
Schizophrenia-Associated Variation in CACNA1C. PLoS One. 2016; 11:e0157086. [PubMed: 
27276213] 
88. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, et al. A polygenic burden 
of rare disruptive mutations in schizophrenia. Nature. 2014; 506:185–90. [PubMed: 24463508] 
89. Andrade A, Hope J, Allen A, Yorgan V, Lipscombe D, Pan JQ. A rare schizophrenia risk variant of 
CACNA1I disrupts CaV3 channel activity. Sci Rep. 2016; 6:34233. [PubMed: 27756899] 
90. Macdonald ML, Alhassan J, Newman JT, Richard M, Gu H, Kelley RM, Sampson AR, Fish KN, 
Penzes P, Wills ZP, Lewis DA, Sweet RA. Selective Loss of Smaller Spines in Schizophrenia. Am 
J Psychiatry. 2017
91. Briggs CA, Chakroborty S, Stutzmann GE. Emerging pathways driving early synaptic pathology in 
Alzheimer’s disease. Biochem Biophys Res Commun. 2017; 483:988–97. [PubMed: 27659710] 
92. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms 
in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013; 
9:602–08. [PubMed: 23562430] 
93. Corvin A, Craddock N, Sullivan PF. Genome-wide association studies: a primer. Psychol Med. 
2010; 40:1063–77. [PubMed: 19895722] 
DeMichele-Sweet et al. Page 16
Mol Psychiatry. Author manuscript; available in PMC 2018 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Diagram of the study design and workflow
Abbreviations used: ACE: Fundació ACE Barcelona Alzheimer Treatment and Research 
Center; ADRC: University of Pittsburgh Alzheimer Disease Research Center; NIA LOAD: 
National Institute on Aging’s Late Onset Alzheimer’s Disease Family Study; NIMH: 
National Institute of Mental Health Genetics Initiative AD Cohort; UK: Genetic and 
Environmental Risk in AD Consortium 1; ADC: consortium of National Institute on Aging 
Alzheimer Disease Centers; CHS: Cardiovascular Health Study; AD-P: Alzheimer disease 
without psychosis; AD+P: Alzheimer disease with psychosis; SCZ: schizophrenia; GWAS: 
Genome-wide association study
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Figure 2. Discovery (a) and replication (b) analysis of AD+P risk SNPs
A. 67 SNPs reached p < 5e-4 in Stage 2 samples (dashed line). B. Stage 3 examined 60 of 
the 67 SNPS, three of which (top blue circles, Table 3) approached significance in meta-
analysis (P = 1.61×10−6). In blue, SNPs showing same risk allele in Stages 2 and 3; red, 
Stage 2 versus 3 results differ in sign (risk allele); size of circle reflects meta-analysis 
−log10(P).
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Fig. 3. Relationship between schizophrenia risk score and risk of psychosis in AD
Displayed are the risk scores for each subject, the score for schizophrenia uses the allele 
found to confer risk in 30, whereas the AD+P aligned score uses the same SNPs but assigns 
risk according to the AD+P association results. Red and blue circles indicate AD+P and AD-
P subjects, respectively.
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Table 1
Cohort subject characteristics.
AD-P
N(%) or Mean (SD)
AD+P
N(%) or Mean (SD)
Total
N (%) or Mean (SD)
A. Discovery Cohort
N 1115 (38.8) 1761 (61.2) 2876 (100)
Female 722 (64.8) 1262 (71.7) 1984 (69.0)
AOO 75.5 (7.8) 74.1 (7.3) 74.6 (7.5)
Age 80.6 (7.3) 81.0 (6.8) 80.8 (7.0)
Last MMSE 14.6 (6.7) 12.0 (7.2) 13.2 (7.1)
B. Replication Cohort
N 1460 (66.5) 734 (33.5) 2194 (100)
Female 905 (62.0) 496 (67.6) 1401 (63.8)
AOO 74.6 (8.2) 74.7 (7.4) 74.6 (8.0)
Age 80.5 (7.8) 81.2 (7.1) 80.7 (7.6)
Last MMSE 16.6 (6.6) 14.3 (7.4) 15.9 (6.9)
AD-P: Alzheimer disease without psychosis; AD+P: Alzheimer disease with psychosis; AOO: age of onset; MMSE: Mini mental state exam
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